Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
RaQualia Expands Alliance with HK inno.N, Licenses Japan Rights to Reflux Therapy
RaQualia Pharma said on December 12 that its board has approved an expansion of its capital and business alliance with South Korea’s HK inno.N, including a plan to license the Japanese rights to its gastric acid reducer tegoprazan. Under the…
To read the full story
Related Article
- RaQualia Partner Files US NDA for Tegoprazan
January 14, 2026
- RaQualia’s Reflux Therapy Tegoprazan Debuts in India
September 18, 2025
- RaQualia’s Acid Reducer Now Available in 5 Latin American Countries
December 13, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Malaysia
September 27, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Colombia
September 3, 2024
- RaQualia’s Acid Reducer Tegoprazan Now Available in Singapore
September 5, 2023
- RaQualia’s Acid Reducer Tegoprazan Launched in Indonesia
July 12, 2023
- RaQualia’s Acid Reducer Tegoprazan Approved in Singapore
January 16, 2023
- RaQualia’s Acid Reducer Tegoprazan Now Available in China
May 10, 2022
BUSINESS
- GNI Targets Above-Industry Growth in Japan after Ayumi Buyout
July 3, 2026
- Sawai Prevails in ALS Drug Contract Appeal against Neugen
July 3, 2026
- Insilico, Takeda Ink AI Drug Discovery Deal Worth Up to US$600 Million
July 3, 2026
- Otsuka’s Voyxact Shows Two-Year Kidney Benefit in PIII IgAN Trial
July 3, 2026
- PeptiDream, NCC Start FIH Study of CLDN18.2 Radiopharmaceutical
July 3, 2026
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…